Advertisement

Archives of Gynecology and Obstetrics

, Volume 298, Issue 3, pp 663–671 | Cite as

New trial of progestin-primed ovarian stimulation using dydrogesterone versus a typical GnRH antagonist regimen in assisted reproductive technology

  • Nanako Iwami
  • Miho Kawamata
  • Naoko Ozawa
  • Takahiro Yamamoto
  • Eri Watanabe
  • Osamu Moriwaka
  • Hirobumi Kamiya
Gynecologic Endocrinology and Reproductive Medicine
  • 38 Downloads

Abstract

Purpose

To compare the clinical and ongoing pregnancy rates between a protocol using oral dydrogesterone with human menopausal gonadotropin (HMG) for progestin-primed ovarian stimulation (PPOS) and the typical gonadotropin-releasing hormone (GnRH) antagonist regimen in women undergoing controlled ovarian hyperstimulation (COH).

Methods

This was a prospective, controlled study of 251 women who underwent COH for in vitro fertilization between October 2016 and July 2017. The patients were allocated alternately into two groups: a dydrogesterone protocol (study group) and a GnRH antagonist protocol (control group). In study group, dydrogesterone (20 mg/day) plus HMG (150 or 225 IU) were administered simultaneously beginning on days 2 or 3 of the menstrual cycle. In both groups, all high-quality embryos were cryopreserved for later transfer. The primary outcome was the ongoing pregnancy rate at 12 weeks per frozen–thawed embryo transfer (FET) and the secondary outcome was the clinical pregnancy rate.

Results

None of the patients experienced a premature luteinizing hormone surge. During the follow-up period, 397 FET cycles were completed. The ongoing pregnancy rates at 12 weeks were 40.0% in study group versus 38.1% in control group (absolute difference 1.9%; 95% CI − 6.83 to 17.2%). The clinical pregnancy rate in study group (52.8%) was also not inferior to that in control group (49.5%; absolute difference 3.3%; 95% CI − 4.02 to 20.2%).

Conclusions

The clinical and ongoing pregnancy rates in study group were comparable to those in control group. Therefore, PPOS with dydrogesterone is a reasonable option to provide COH.

Keywords

Dydrogesterone Progestin-primed ovarian stimulation Premature LH surge GnRH antagonist Controlled ovarian stimulation 

Abbreviations

AMH

Anti-Müllerian hormone

ART

Assisted reproductive technology

BMI

Body mass index

CI

Confidence interval

COCs

Cumulus–oocyte complexes

COH

Controlled ovarian hyperstimulation

E2

Estradiol 2

FET

Frozen embryo transfer

GnRH

Gonadotropin-releasing hormone

hCG

Human chorionic gonadotropin

HMG

Human menopausal gonadotropin

HRT

Hormone replacement therapy

IVF

In vitro fertilization

ICSI

Intra-cytoplasmic sperm injection

LH

Luteinizing hormone

OHSS

Ovarian hyperstimulation syndrome

P4

Progesterone

PPOS

Progestin-primed ovarian stimulation

SD

Standard deviation

USD

United States dollar

Notes

Acknowledgements

The authors wish to thank Ms. Mika Matsuoka for data collection, and Ms. Nami Hirayama and Ms. Yumiko Kobayashi for statistical analysis (clinical staff in the Kamiya Ladies Clinic). We also thank Dr. Shigeo Araki (Chief Director of the International Institute of Medical Technology IMT College) and Dr. Daiki Iwami (staff member of the Department of Renal and Genitourinary Surgery, Hokkaido University, Graduate School of Medicine) for proofreading the manuscript, and Dr. Kota Ono (staff member of the Department of Biostatistics, Hokkaido University, Graduate School of Medicine) as a statistical adviser. We thank Ellen Knapp, PhD, and James Cummins, PhD, from Edanz Group (http://www.edanzediting.com/ac) for editing drafts of this manuscript.

Author contribution

NI: Protocol development, data analysis, data collection, manuscript writing. MK: Data collection. NO: Data collection. TY: Data collection. EW: Data collection. OM: Data collection. HK: Data collection, protocol development.

Funding

None.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in this study were in accordance with the ethical standards of the Kamiya Ladies Clinic and with the 1964 Helsinki declaration and its later amendments or similar ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Firouzabadi RD, Ahmadi S, Oskouian H, Davar R (2010) Comparing GnRH agonist long protocol and GnRH antagonist protocol in outcome the first cycle of ART. Arch Gynecol Obstet 281(1):81–85.  https://doi.org/10.1007/s00404-009-1073-5 CrossRefPubMedGoogle Scholar
  2. 2.
    Mourad S, Brown J, Farquhar C (2017) Interventions for the prevention of OHSS in ART cycles: an overview of Cochrane reviews. Cochrane Database Syst Rev 1:CD012103.  https://doi.org/10.1002/14651858.cd012103.pub2 PubMedGoogle Scholar
  3. 3.
    Al-Inany HG, Youssef MA, Ayeleke RO, Brown J, Lam WS, Broekmans FJ (2016) Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev 4:CD001750.  https://doi.org/10.1002/14651858.cd001750.pub4 PubMedGoogle Scholar
  4. 4.
    Reichman DE, Zakarin L, Chao K, Meyer L, Davis OK, Rosenwaks Z (2014) Diminished ovarian reserve is the predominant risk factor for gonadotropin-releasing hormone antagonist failure resulting in breakthrough luteinizing hormone surges in in vitro fertilization cycles. Fertility Steril 102(1):99–102.  https://doi.org/10.1016/j.fertnstert.2014.04.010 CrossRefGoogle Scholar
  5. 5.
    Kuang Y, Chen Q, Fu Y, Wang Y, Hong Q, Lyu Q, Ai A, Shoham Z (2015) Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertility Steril 104(1):62–70.e63.  https://doi.org/10.1016/j.fertnstert.2015.03.022 CrossRefGoogle Scholar
  6. 6.
    Zhu X, Ye H, Fu Y (2016) The utrogestan and hMG protocol in patients with polycystic ovarian syndrome undergoing controlled ovarian hyperstimulation during IVF/ICSI treatments. Medicine (Baltimore) 95(28):e4193.  https://doi.org/10.1097/md.0000000000004193 CrossRefGoogle Scholar
  7. 7.
    Wang Y, Chen Q, Wang N, Chen H, Lyu Q, Kuang Y (2016) Controlled ovarian stimulation using medroxyprogesterone acetate and hMG in patients with polycystic ovary syndrome treated for IVF: a double-blind randomized crossover clinical trial. Medicine (Baltimore) 95(9):e2939.  https://doi.org/10.1097/MD.0000000000002939 CrossRefGoogle Scholar
  8. 8.
    Zhu X, Ye H, Fu Y (2017) Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic sperm injection treatments in combination with embryo cryopreservation. Fertility Steril 108(3):505–512.  https://doi.org/10.1016/j.fertnstert.2017.06.017 (e502) CrossRefGoogle Scholar
  9. 9.
    Kuang Y, Hong Q, Chen Q, Lyu Q, Ai A, Fu Y, Shoham Z (2014) Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection treatment, with optimal pregnancy outcomes in frozen–thawed embryo transfer cycles. Fertility Steril 101(1):105–111.  https://doi.org/10.1016/j.fertnstert.2013.09.007 CrossRefGoogle Scholar
  10. 10.
    Wang N, Wang Y, Chen Q, Dong J, Tian H, Fu Y, Ai A, Lyu Q, Kuang Y (2016) Luteal-phase ovarian stimulation vs conventional ovarian stimulation in patients with normal ovarian reserve treated for IVF: a large retrospective cohort study. Clin Endocrinol (Oxf) 84(5):720–728.  https://doi.org/10.1111/cen.12983 CrossRefGoogle Scholar
  11. 11.
    Kwik M, Maxwell E (2016) Pathophysiology, treatment and prevention of ovarian hyperstimulation syndrome. Curr Opin Obstet Gynecol 28(4):236–241.  https://doi.org/10.1097/gco.0000000000000284 CrossRefPubMedGoogle Scholar
  12. 12.
    Atkinson P, Koch J, Ledger WL (2014) GnRH agonist trigger and a freeze-all strategy to prevent ovarian hyperstimulation syndrome: a retrospective study of OHSS risk and pregnancy rates. Aust N Z J Obstet Gynaecol 54(6):581–585.  https://doi.org/10.1111/ajo.12277 CrossRefPubMedGoogle Scholar
  13. 13.
    Yu S, Long H, Chang HY, Liu Y, Gao H, Zhu J, Quan X, Lyu Q, Kuang Y, Ai A (2018) New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Hum Reprod 33(2):229–237.  https://doi.org/10.1093/humrep/dex367 CrossRefPubMedGoogle Scholar
  14. 14.
    Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH (2008) Classification and pharmacology of progestins. Maturitas 61(1–2):171–180CrossRefPubMedGoogle Scholar
  15. 15.
    Schindler AE (2009) Progestational effects of dydrogesterone in vitro, in vivo and on the human endometrium. Maturitas 65(Suppl 1):S3–11.  https://doi.org/10.1016/j.maturitas.2009.10.011 CrossRefPubMedGoogle Scholar
  16. 16.
    Nadarajah R, Rajesh H, Wong KY, Faisal F, Yu SL (2016) Live birth rates and safety profile using dydrogesterone for luteal phase support in assisted reproductive techniques. Singap Med J.  https://doi.org/10.11622/smedj.2016080 Google Scholar
  17. 17.
    Cummins JM, Breen TM, Harrison KL, Shaw JM, Wilson LM, Hennessey JF (1986) A formula for scoring human embryo growth rates in in vitro fertilization: its value in predicting pregnancy and in comparison with visual estimates of embryo quality. J In Vitro Fertilization Embryo Transf 3(5):284–295CrossRefGoogle Scholar
  18. 18.
    Toftager M, Bogstad J, Bryndorf T, Lossl K, Roskaer J, Holland T, Praetorius L, Zedeler A, Nilas L, Pinborg A (2016) Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles. Hum Reprod 31(6):1253–1264.  https://doi.org/10.1093/humrep/dew051 CrossRefPubMedGoogle Scholar
  19. 19.
    Robert J (2009) Guidance for industry non-inferiority clinical trials. Food and Drug Administration, US Department of Health and Human Services Publishing online. https://www.fda.gov/downloads/drugs/drugsafety/informationbydrugclass/ucm187447.pdf. Accessed 31 July 2018
  20. 20.
    Althunian TA, de Boer A, Groenwold RHH, Klungel OH (2017) Defining the noninferiority margin and analysing noninferiority: an overview. Br J Clin Pharmacol 83(8):1636–1642.  https://doi.org/10.1111/bcp.13280 CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Hahn S (2012) Understanding noninferiority trials. Korean. J Pediatr 55(11):403–407.  https://doi.org/10.3345/kjp.2012.55.11.403 Google Scholar
  22. 22.
    Zhu X, Zhang X, Fu Y (2015) Utrogestan as an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Medicine (Baltimore) 94(21):e909.  https://doi.org/10.1097/MD.0000000000000909 CrossRefGoogle Scholar
  23. 23.
    Messinis IE (2006) Ovarian feedback, mechanism of action and possible clinical implications. Hum Reprod Update 12(5):557–571.  https://doi.org/10.1093/humupd/dml020 CrossRefPubMedGoogle Scholar
  24. 24.
    Soules MR, Steiner RA, Clifton DK, Cohen NL, Aksel S, Bremner WJ (1984) Progesterone modulation of pulsatile luteinizing hormone secretion in normal women. J Clin Endocrinol Metab 58(2):378–383.  https://doi.org/10.1210/jcem-58-2-378 CrossRefPubMedGoogle Scholar
  25. 25.
    Harris TG, Dye S, Robinson JE, Skinner DC, Evans NP (1999) Progesterone can block transmission of the estradiol-induced signal for luteinizing hormone surge generation during a specific period of time immediately after activation of the gonadotropin-releasing hormone surge-generating system. Endocrinology 140(2):827–834.  https://doi.org/10.1210/endo.140.2.6490 CrossRefPubMedGoogle Scholar
  26. 26.
    Richter TA, Robinson JE, Evans NP (2002) Progesterone blocks the estradiol-stimulated luteinizing hormone surge by disrupting activation in response to a stimulatory estradiol signal in the ewe. Biol Reprod 67(1):119–125CrossRefPubMedGoogle Scholar
  27. 27.
    Richter TA, Robinson JE, Lozano JM, Evans NP (2005) Progesterone can block the preovulatory gonadotropin-releasing hormone/luteinising hormone surge in the ewe by a direct inhibitory action on oestradiol-responsive cells within the hypothalamus. J Neuroendocrinol 17(3):161–169.  https://doi.org/10.1111/j.1365-2826.2005.01287.x CrossRefPubMedGoogle Scholar
  28. 28.
    Pohl CR, Richardson DW, Marshall G, Knobil E (1982) Mode of action of progesterone in the blockade of gonadotropin surges in the rhesus monkey. Endocrinology 110(4):1454–1455.  https://doi.org/10.1210/endo-110-4-1454 CrossRefPubMedGoogle Scholar
  29. 29.
    Dierschke DJ, Yamaji T, Karsch FJ, Weick RF, Weiss G, Knobil E (1973) Blockade by progesterone of estrogen-induced LH and FSH release in the rhesus monkey. Endocrinology 92(5):1496–1501.  https://doi.org/10.1210/endo-92-5-1496 CrossRefPubMedGoogle Scholar
  30. 30.
    Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH (2003) Classification and pharmacology of progestins. Maturitas 46(Suppl 1):S7–S16CrossRefPubMedGoogle Scholar
  31. 31.
    Schindler AE (2016) Present and future aspects of dydrogesterone in prevention or treatment of pregnancy disorders: an outlook. Horm Mol Biol Clin Investig 27(2):49–53.  https://doi.org/10.1515/hmbci-2016-0028 PubMedGoogle Scholar
  32. 32.
    Tournaye H, Sukhikh GT, Kahler E, Griesinger G (2017) A Phase III randomized controlled trial comparing the efficacy, safety and tolerability of oral dydrogesterone versus micronized vaginal progesterone for luteal support in in vitro fertilization. Hum Reprod 32(5):1019–1027.  https://doi.org/10.1093/humrep/dex023 CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Zhu X, Ye H, Fu Y (2017) Use of utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection treatments in combination with a “freeze all” strategy: a randomized controlled dose-finding study of 100 mg versus 200 mg. Fertility Steril 107(2):379–386.  https://doi.org/10.1016/j.fertnstert.2016.10.030 (e374) CrossRefGoogle Scholar
  34. 34.
    Ubaldi FM, Capalbo A, Vaiarelli A, Cimadomo D, Colamaria S, Alviggi C, Trabucco E, Venturella R, Vajta G, Rienzi L (2016) Follicular versus luteal phase ovarian stimulation during the same menstrual cycle (DuoStim) in a reduced ovarian reserve population results in a similar euploid blastocyst formation rate: new insight in ovarian reserve exploitation. Fertility Steril 105(6):1488–1495.e1481.  https://doi.org/10.1016/j.fertnstert.2016.03.002 CrossRefGoogle Scholar
  35. 35.
    Griffin D, Benadiva C, Kummer N, Budinetz T, Nulsen J, Engmann L (2012) Dual trigger of oocyte maturation with gonadotropin-releasing hormone agonist and low-dose human chorionic gonadotropin to optimize live birth rates in high responders. Fertility Steril 97(6):1316–1320.  https://doi.org/10.1016/j.fertnstert.2012.03.015 CrossRefGoogle Scholar
  36. 36.
    Zelinski-Wooten MB, Hutchison JS, Hess DL, Wolf DP, Stouffer RL (1995) Follicle stimulating hormone alone supports follicle growth and oocyte development in gonadotrophin-releasing hormone antagonist-treated monkeys. Hum Reprod 10(7):1658–1666CrossRefPubMedGoogle Scholar
  37. 37.
    Imoedemhe DA, Sigue AB, Pacpaco EL, Olazo AB (1991) Stimulation of endogenous surge of luteinizing hormone with gonadotropin-releasing hormone analog after ovarian stimulation for in vitro fertilization. Fertility Steril 55(2):328–332CrossRefGoogle Scholar
  38. 38.
    Humaidan P, Bredkjaer HE, Bungum L, Bungum M, Grondahl ML, Westergaard L, Andersen CY (2005) GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod 20(5):1213–1220.  https://doi.org/10.1093/humrep/deh765 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Reproductive HealthKamiya Ladies ClinicSapporoJapan

Personalised recommendations